metricas
covid
Buscar en
Revista Española de Cirugía Ortopédica y Traumatología (English Edition)
Toda la web
Inicio Revista Española de Cirugía Ortopédica y Traumatología (English Edition) Tranexamic acid in orthopaedic surgery: A paradigm shift in transfusion
Información de la revista
Vol. 64. Núm. 1.
Páginas 1-3 (enero - febrero 2020)
Visitas
940
Vol. 64. Núm. 1.
Páginas 1-3 (enero - febrero 2020)
Editorial
Acceso a texto completo
Tranexamic acid in orthopaedic surgery: A paradigm shift in transfusion
Ácido tranexámico en cirugía ortopédica: un cambio de paradigma transfusional
Visitas
940
M. Basoraa,
Autor para correspondencia
mbasora@clinic.cat

Corresponding author.
, M.J. Colominab,c
a Servicio de Anestesiología y Reanimación, Hospital Clínic, Barcelona, Spain
b Servicio de Anestesiología y Cuidados Críticos de Anestesiología, Hospital Universitari Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
c Universitat de Barcelona, Barcelona, Spain
Este artículo ha recibido
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Texto completo

The strategy on the correct management of the patient’s blood pool and transfusion in routine orthopaedic procedures, such as total hip arthroplasty (THA) and total knee arthroplasty (TKA) and spinal surgery, has changed in recent years. In the early 1980s, preoperative autologous blood donation and intra-and post-operative blood retrieval became standard clinical practice, primarily due to fear related to blood-born viral pathogens, and as a strategy to prevent allogeneic transfusion. The rate of allogeneic blood transfusions in elective orthopaedic surgery at that time was above 30%.1

From 2010, the concept of saving blood and allogeneic transfusion was extended with other measures including optimisation of preoperative haemoglobin, minimisation of intraoperative bleeding through the use of antifibrinolytic drugs such as tranexamic acid (TXA), and improvement of the patient’s anaemia tolerance. This entire set of measures no longer focussed on the technique but on the patient, and was accepted in the scientific literature under “Patient Blood Management” (PBM). Its main objective is to improve the clinical outcome by avoiding or minimising unnecessary transfusions. In many centres orthopaedic surgery has been a leader in implementing PBM.1–3

We know that during and immediately after major orthopaedic surgery a hyperfibrinolytic stage is observed that leads to increased bleeding.3,4 Stimuli such as vascular hypoxia, cytokine circulation and endothelial release of the plasminogen activator, as a basic inflammatory response to surgical aggression, catalyse the conversion of plasminogen to plasmin. In addition, the use of ischaemia in knee arthroplasty adds activation of fibrinolysis by releasing fibrinolytic mediators after the tourniquet is released, thus encouraging postoperative bleeding. TXA acts by reversibly blocking the lysine receptor of plasminogen, thus preventing its activation to plasmin and in consequence blocking lysis of polymerised fibrin, thus reducing clot lysis and therefore bleeding.3,4

In orthopaedic surgery, the administration of TXA was initiated in TKA and later THA, spinal surgery, hip and knee replacement arthroplasty.2,3 More recently it has been proposed to reduce bleeding in shoulder arthroplasty surgery and hip fracture surgery, although the degree of evidence is less than in the abovementioned surgeries.

The efficacy of TXA was assessed in a recent meta-analysis in 67 articles selected as best evidence for knee arthroplasty5 (>9000 patients) and 34 for hip arthroplasty6 (1668 patients assessed for bleeding and 2545 patients assessed for transfusion). For TKA and THA the reduction in bleeding was about 300mL and there was a 25% reduction in the transfusion rate. Topical, intravenous and oral formulations of TXA were all superior to placebo in terms of decreased blood loss and transfusion risk, whereas no formulation was clearly superior when compared together. The use of repeated doses of intravenous and oral TXA and higher doses of intravenous and topical TXA did not significantly reduce blood loss or transfusion risk.

In spinal surgery, administration of TXA is effective in reducing bleeding, although not so effective in reducing transfusion requirements.7 The evidence is not as clear as in TKA and THA because the different randomised studies included surgeries of different levels of fusion, aetiologies and sites, and therefore with different risk of bleeding. The results of a recent meta-analysis8 highlight that stratification of the bleeding risk in spinal arthrodesis surgery would make it possible to identify the patients who could benefit most from antifibrinolytic treatment (e.g. 3 or more fusion levels) and the individualisation of the bleeding risk in each case necessary to support the decision for or against its administration.

More recently, TXA has been included for use in hip fracture. Although we do not have strong evidence for its recommendation, in a recent meta-analysis9 including a total of 770 patients from 7 studies, intravenous TXA provided a 46% reduction in transfusion risk with no increased risk of thromboembolic events, but with low quality evidence. Hip fracture surgery causes blood loss, but bleeding begins at the time of fracture. Furthermore, the profile of elderly patients is not the same as that of orthopaedic patients, even in the case of a total hip prosthesis. All these considerations result in a lower efficacy profile and even more uncertain complications and side effects than with elective orthopaedic surgery. Therefore the indication for TXA in hip fracture should be individualised.

Safety of tranexamic acid in orthopaedic surgery

Despite the extensive documentation of the efficacy of TXA in major orthopaedic surgery, we have no large studies detailing clinical safety outcomes, especially those related to thromboembolic events and renal complications in the peri-operative period. Clinical trials often select patients with strict inclusion criteria that do not reflect usual clinical practice, thus generating a significant bias in assessing these side effects.

A review10 of 510 US hospitals and the Premier Perspective database based on notifications for 2006–2012 included 872,416 patients who underwent THA and TKA. On comparing the patients in relation to age and comorbidity index, those treated with TXA (compared to those who were not treated) had a lower rate of thromboembolic complications (.6% vs. .8%), acute kidney failure (1.2 %vs. 1.6%) and combined complications (1.9% vs. 2.6%).

In another review study11 in 73 randomised controlled trials with 6953 patients who underwent major orthopaedic surgery, the overall gross incidence of venous thromboembolism was 2.1% in patients who received intravenous TXA and 2% in the controls.

Another meta-analysis12 that used the ASA classification as a proxy for the presence of comorbidities associated with a high risk of a thromboembolic event (78 randomised clinical trials with 7164 patients) concluded that administration of TXA did not increase the risk of thromboembolic disease in patients undergoing arthroplasty.

Tranexamic acid and administration route

The intravenous route is used most for administering TXA in orthopaedic surgery.2,3 This route will provide us with drug levels in the blood capable of reducing the activity of the tissue plasmin activator by 80% in vitro (10mg/mL). Maximum plasma levels of TXA are rapidly obtained after a short intravenous infusion and diffuse rapidly to the joint fluid and synovial membrane. Its half-life is 3–4h. After administration of an intravenous injection of 10mg/kg to 17 patients treated with a TKA, the concentrations in the joint fluids were similar to those observed in the corresponding serum samples.4

Topical administration of TXA emerged as an alternative to intravenous administration in patients in whom we suspect a thrombotic risk. Plasma levels achieved with intravenous administration of 10mg/kg could be 18mg/L, whereas topical administration of 1.5 and 3g achieved plasma levels of 4.5 and 8.5mg/L respectively.12 Its effectiveness in reducing bleeding and transfusion is similar to intravenous administration as recent studies with a high level of evidence have shown,13,14 although the topical administration route is more heterogeneous. Some studies describe pulverisation of the surgical area, administration through drains, sometimes added to the administration of local anaesthetic by infiltration for postoperative analgesia, which adds more variability to its form of administration.12,15,16 Therefore, in the absence of thrombotic risk factors, intravenous administration seems reasonable to achieve effective and more reproducible plasma levels. Based on the available literature, the administration of multiple or high doses of TXA is not necessary, although its intravenous administration is potentially superior.5,6

Dosage of tranexamic acid

TXA dosage for TKA takes into account that most of these operations are performed with a tourniquet and therefore many of the clinical studies dose between 10mg and 20mg/kg before the release of ischaemia. Some authors have conducted studies by adding a perfusion of 1mg–10mg/kg/h for 3–12h. Other authors have simplified the dosage with 1g before releasing ischaemia and 1g at 3h. In an attempt to compare the studies, in the meta-analysis by Fillingham et al.,5,6 they stratified the dosage and considered a high dose as above 1g or ≥20mg/kg for intravenous administration.

With regard to topical administration in TKA, most studies use total doses between 1g and 3g topically and any dose greater than 1.5g13,14 is considered a high dose. In the case of THA, the North American clinical guidelines published in 201610 recommend the same doses that we have noted for TKA.

In spinal surgery, the most frequently used doses are 10–30mg/kg as the initial dose followed by 1–2mg/kg/h during surgery.8

Action protocols

The evidence on the effectiveness and safety of TXA treatment in orthopaedic surgery should result in this treatment being included in all protocols of the different centres where these surgeries are performed.

It is advisable to reach a consensus with all of the team participating in the peri-operative period and reach an agreement on the form of administration, route, dose and dosage.3 Added to this, it would be both desirable and essential to review the transfusion practice for these patients in hospital wards and to adapt them to the change produced by administration of TXA. It is advisable to review the transfusion protocol and make decisions regarding the prescription of packed red blood cells, informing all professionals involved in the transfusion process (anaesthesiology, on-call doctors, nurses and rehabilitators).17

To conclude, the cultural change in recent years with the inclusion of TXA in orthopaedic operating theatres has lead to a paradigm shift in the management of surgical bleeding.

Level of evidence

Level of evidence I.

Funding

None.

Conflict of interests

The authors have no conflict of interests to declare.

References
[1]
F. Canillas, S. Gómez-Ramírez, J.A. García-Erce, J. Pavía-Molina, M. Muñoz.
“Patient blood management” en cirugía ortopédica.
Rev Esp Cir Ortop, 59 (2015), pp. 137-149
[2]
X. Aguilera-Roig, M. Jordán-Sales, L. Natera-Cisneros, J.C. Monllau-García, M.J. Martínez-Zapata.
Ácido tranexámico en cirugía ortopédica.
Rev Esp Cir Ortop, 58 (2014), pp. 52-56
[3]
S. Moráis, M. Ortega-Andreu, E.C. Rodríguez-Merchán, N.G. Padilla-Eguiluz, H. Pérez-Chrzanowska, R. Figueredo-Zalve, et al.
Blood transfusion after primary total knee arthroplasty can be significantly minimised through a multimodal blood-loss prevention approach.
Int Orthop, 38 (2014), pp. 347-354
[4]
A. Blanié, L. Bellamy, Y. Rhayem, C. Flaujac, C.M. Samama, M. Fontenay, et al.
Duration of postoperative fibrinolysis after total hip or knee replacement: a laboratory follow-up study.
Thromb Res, 131 (2013), pp. e6-e11
[5]
Y.A. Fillingham, D.B. Ramkumar, D.S. Jevsevar, A.J. Yates, P. Shores, K. Mullen, et al.
The efficacy of tranexamic acid in total knee arthroplasty: a network meta-analysis.
J Arthroplasty, 33 (2018), pp. 3090-3098
[6]
Y.A. Fillingham, D.B. Ramkumar, D.S. Jevsevar, A.J. Yates, P. Shores, K. Mullen, et al.
The efficacy of tranexamic acid in total hip arthroplasty: a network meta-analysis.
J Arthroplasty, 33 (2018), pp. 3083-3089
[7]
M.J. Colomina, M. Koo, M. Basora, J. Pizones, L. Mora, J. Bagó.
Intraoperative tranexamic acid use in major spine surgery in adults: a multicentre, randomized, placebo-controlled trial.
Br J Anaesth, 118 (2017), pp. 380-390
[8]
V.M. Lu, Y.T. Ho, M. Nambiar, R.J. Mobbs, K. Phan.
The perioperative efficacy and safety of antifibrinolytics in adult spinal fusion surgery: a systematic review and meta-analysis.
Spine (Phila Pa 1976), 43 (2018), pp. E949-E958
[9]
L.S. Farrow, T.O. Smith, G.P. Ashcroft, P.K. Myint.
A systematic review of tranexamic acid in hip fracture surgery.
Br J Clin Pharmacol, 82 (2016), pp. 1458-1470
[10]
J. Poeran, R. Rasul, S. Suzuki, T. Danninger, M. Mazumdar, M. Opperer, et al.
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
BMJ, 12 (2014), pp. g4829
[11]
M. Franchini, C. Mengoli, M. Marietta, G. Marano, S. Vaglio, S. Pupella, et al.
Safety of intravenous tranexamic acid in patients undergoing major orthopaedic surgery: a meta-analysis of randomised controlled trials.
Blood Transfus, 16 (2018), pp. 36-43
[12]
Y.A. Fillingham, D.B. Ramkumar, D.S. Jevsevar, A.J. Yates, S.A. Bini, H.D. Clarke, et al.
Tranexamic acid use in total joint arthroplasty: the clinical practice guidelines endorsed by the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, Hip Society, and Knee Society.
J Arthroplasty, 33 (2018), pp. 3065-3069
[13]
E. Gomez-Barrena, M. Ortega-Andreu, N.G. Padilla-Eguiluz, H. Pérez-Chrzanowska, R. Figueredo-Zalve.
Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial.
J Bone Jt Surg Am, 3 (2014), pp. 1937-1944
[14]
E.C. Rodriguez-Merchan, M. Ortega-Andreu, N.G. Padilla-Eguiluz, P. Gomez-Cardero, Á Martinez-Lloreda, E. Gomez-Barrena.
Low-volume formulation of intra-articular tranexamic acid, 25-ml tranexamic acid (2.5 g) plus 20-ml saline, is effective in decreasing blood transfusion rate in primary total knee replacement even without preoperative haemoglobin optimization.
Blood Coagul Fibrinolysis, 27 (2016), pp. 660-666
[15]
J. Wong, A. Abrishami, H. El Beheiry, N.N. Mahomed, J. Roderick Davey, R. Gandhi, et al.
Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty: a randomized, controlled trial.
J Bone Jt Surg Am, 92 (2010), pp. 2503-2513
[16]
S. Alshryda, M. Sukeik, P. Sarda, J. Blenkinsopp, F.S. Haddad, J.M. Mason.
A systematic review and meta-analysis of the topical administration of tranexamic acid in total hip and knee replacement.
Bone Jt J, 96-B (2014), pp. 1005-1015
[17]
E. Gómez-Barrena, M. Ortega-Andreu.
Widespread of total knee arthroplasty perioperative blood management techniques based on tranexamic acid: barriers and opportunities.

Please cite this article as: Basora M, Colomina MJ. Ácido tranexámico en cirugía ortopédica: un cambio de paradigma transfusional. Rev Esp Cir Ortop Traumatol. 2020;64:1–3.

Copyright © 2019. SECOT
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos